Elsevier

The Lancet

Volume 344, Issues 8939–8940, 24 December 1994, Pages 1768-1769
The Lancet

Letters to the Editor
Short-course cimetidine and survival with colorectal cancer

https://doi.org/10.1016/S0140-6736(94)92907-6Get rights and content

References (5)

There are more references available in the full text version of this article.

Cited by (82)

  • Pharmacological interventions part IV: Metabolic modifiers

    2020, An Innovative Approach to Understanding and Treating Cancer: Targeting pH: From Etiopathogenesis to New Therapeutic Avenues
  • Old wine in new bottles: Drug repurposing in oncology

    2020, European Journal of Pharmacology
    Citation Excerpt :

    As far as colorectal cancer is concerned, there were a few randomized studies over several years on the use of cimetidine in patients with this type of cancer (Adams and Morris, 1994; Jameson et al., 2018; Kelly et al., 1999; Matsumoto et al., 2002; Svendsen et al., 1995). In 1994, it was found that perioperative treatment with cimetidine for seven days may reduce the immunosuppressive effect of surgery in patients with Dukes stage A, B and C tumours, undergoing resection of colorectal cancer, compared with randomized control groups (Adams and Morris, 1994). Nevertheless, Svendsen et al. have noted that cimetidine does not reduce mortality in patients with colorectal cancer who had undergone a resection or an exploratory operation for adenocarcinoma of the colon or rectum, and its use may result only in the positive tendency toward a survival benefit in patients undergoing surgery for Dukes stage C colorectal carcinoma (Svendsen et al., 1995).

  • Operative Approach to Rectal Cancer: An Anatomical and Technical Description

    2018, Surgical Oncology
    Citation Excerpt :

    In addition to the critical steps to ensure enbloc resection of the mesorectal envelope, it is important to emphasize that the circumferential radial margin (CRM), or measurement of the margin on the non-peritonealized surface of the resected rectal specimen must be carefully evaluated. The CRM may be an important determinant of need for subsequent adjuvant therapies as an involved CRM has been shown to have prognostic significance for local recurrence. [29] Wibe et al. retrospectively studied 686 patients with a known margin; 22% of those patients with an involved CRM developed local recurrence versus 5% of those who had a negative margin [30].

  • The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer

    2014, Cancer Treatment Reviews
    Citation Excerpt :

    Although shown to decrease post-operative CRP in patients without cancer,118 the effects of H2RA use on systemic cytokine profiles and biomarkers of the systemic inflammatory response in patients with CRC remains unknown. The first reports of a survival advantage for H2RAs in patients with CRC were in the early 1990s, when Adams and co-workers reported a non-significant increase in 3-year survival with peri-operative cimetidine in patients with Dukes A to C CRC (3-year survival 93% vs. 59%, p = 0.17).112 In 1995, Matsumoto and co-workers reported the survival analysis of a multicentre, randomised controlled trial of the effects of cimetidine on adjuvant 5-fluorouracil-induced appetite loss and oesophagitis.119

View all citing articles on Scopus
View full text